[HTML][HTML] Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic …
MA Sekeres, M Othus, AF List, O Odenike… - Journal of Clinical …, 2017 - ncbi.nlm.nih.gov
Journal of Clinical Oncology, 2017•ncbi.nlm.nih.gov
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With
Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia:
North American Intergroup Study SWOG S1117 - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List J
Clin Oncol PMC5562170 Other Formats PDF (893K) Actions Cite Collections Share Permalink …
Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia:
North American Intergroup Study SWOG S1117 - PMC Back to Top Skip to main content NIH
NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Search PMC Full-Text Archive Search in PMC Advanced Search User Guide Journal List J
Clin Oncol PMC5562170 Other Formats PDF (893K) Actions Cite Collections Share Permalink …
Abstract
Purpose
Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) to azacitidine is not known.
ncbi.nlm.nih.gov